National Pension Service increased its stake in AbbVie Inc (NYSE:ABBV) by 6.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,424,538 shares of the company’s stock after buying an additional 85,336 shares during the period. National Pension Service’s holdings in AbbVie were worth $114,704,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the stock. Prime Capital Investment Advisors LLC acquired a new position in AbbVie in the fourth quarter worth $27,000. Penserra Capital Management LLC acquired a new position in AbbVie in the fourth quarter worth $32,000. Larson Financial Group LLC acquired a new position in AbbVie in the fourth quarter worth $37,000. Horrell Capital Management Inc. acquired a new position in AbbVie in the fourth quarter worth $41,000. Finally, Capital Financial Planning LLC acquired a new position in AbbVie in the fourth quarter worth $41,000. Institutional investors and hedge funds own 69.91% of the company’s stock.
In other news, EVP Azita Saleki-Gerhardt sold 15,797 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $79.03, for a total transaction of $1,248,436.91. Following the completion of the transaction, the executive vice president now owns 93,312 shares of the company’s stock, valued at $7,374,447.36. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Brian L. Durkin sold 475 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $79.69, for a total transaction of $37,852.75. Following the transaction, the vice president now directly owns 9,121 shares of the company’s stock, valued at approximately $726,852.49. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,272 shares of company stock valued at $3,286,290. Corporate insiders own 0.08% of the company’s stock.
Shares of ABBV opened at $80.06 on Friday. AbbVie Inc has a 1 year low of $75.62 and a 1 year high of $103.16. The firm has a market cap of $118.36 billion, a PE ratio of 10.12, a PEG ratio of 1.65 and a beta of 1.14.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Thursday, April 25th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.08. AbbVie had a net margin of 16.42% and a negative return on equity of 221.09%. The company had revenue of $7.83 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter in the previous year, the company posted $1.87 earnings per share. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. Sell-side analysts expect that AbbVie Inc will post 8.83 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://sportsperspectives.com/2019/05/26/abbvie-inc-abbv-shares-bought-by-national-pension-service.html.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Further Reading: What is a good rate of return for a mutual fund?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.